It is made available under a CC-BY-NC-ND 4.0 International license .

A meta-analysis on the role of pre-existing chronic disease in the cardiac complications of SARS-CoV-2 infection

- Jane E. Sinclair¹, Yanshan Zhu¹, Gang Xu², Wei Ma^{3,4}, Haiyan Shi⁵, Kun-Long Ma⁶, Chun-Feng Cao⁶, Ling-Xi Kong⁶, Ke-Qiang Wan⁶, Juan Liao⁶, Hai-Qiang Wang⁷, Matt Arentz⁸, Meredith Redd¹², Linda A. Gallo¹³, & Kirsty R. Short^{1,14*}
- ¹ School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia
- ² Guangzhou First People's Hospital, Guangzhou, Guangdong, China
- ³ Department of Geriatric Medicine, Guangzhou First People's Hospital, Guangzhou, Guangdong, China
- ⁴ School of Medicine, South China University of Technology, Guangzhou, Guangdong, China
- ⁵ Department of Respiratory Medicine, Guangzhou Eighth People's Hospital, Guangzhou, Guangdong, China
- ⁶ Yongchuan Hospital of Chongqing Medical University, Yongchuan, Chongqing, China
- ⁷ Institute of Integrative Medicine, Shaanxi University of Chinese Medicine, Xi'an Shaanxi Province, China
- ⁸ Department of Global Health, University of Washington, Seattle, Washington, U.S.A.
- ¹² Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia
- ¹³ School of Biomedical Sciences, The University of Queensland, Brisbane, Australia
- ¹⁴ School of Public Health. The University of Oueensland, Brisbane, Australia
- * Correspondence: k.short@uq.edu.au; Tel.: +61 7 336 54226

JES: Bachelors	K-LM: MD	H-QW: MD/PhD
YZ: Masters	C-FC: MD	MA: MD
GX: MD	L-XK: MD	MR: PhD
WM: MD	K-QW: MD	LAG: PhD
HS: MD	JL: MD	KRS: PhD

It is made available under a CC-BY-NC-ND 4.0 International license .

30 SUMMARY

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with multiple direct and indirect cardiovascular complications. It is not yet well defined whether the patient groups at increased risk of SARS-CoV-2 severe respiratory disease experience similarly heightened incidence of cardiovascular complications. We sought to analyse the role of host co-morbidities (chronic respiratory illnesses, cardiovascular disease (CVD), hypertension or diabetes mellitus (DM)) in the acute cardiovascular complications associated with SARS-CoV-2 infection.

37 Methods: We retrospectively investigated published and pre-printed, publicly released, de-identified, data 38 made available between Dec 1, 2019, and October 14, 2020. Information was accessed from PubMed, Embase, 39 medRxiv and SSRN. 363 full-text articles were reviewed and 283 excluded for lack of original research, 40 irrelevance to outcome, inappropriate cohort, or describing case reports of <10 patients. Data were extracted 41 from 25 studies and the remaining 55 contacted to request appropriate data, to which four responded with data 42 contributions. A final of 29 studies were included. This systematic review was conducted based on Preferred 43 Reporting Items for Systematic Reviews (PRISMA) and Meta-analyses of Observational Studies in 44 Epidemiology (MOOSE) statements. Included studies were critically appraised using Newcastle Ottawa Quality Assessment Scale (NOS). Data were extracted independently by multiple observers. When $I^2 \square < \square 50\%$, a 45 46 fixed \square effects model was selected, while a random-effects model was employed when $I^2 \square > 50\%$. 47 Cardiovascular complications were measured as blood levels of cardiac biomarkers above the 99th percentile 48 upper reference limit, new abnormalities in electrocardiography, and/or new abnormalities in echocardiography.

Results: Individual analyses of the majority of studies found that the median age was higher by approximately 10 years in patients with cardiovascular complications. Pooled analyses showed the development of SARS-CoV-2 cardiovascular complications was significantly increased in patients with chronic respiratory illness (Odds Ratio (OR) 1.67[1.48,1.88]), CVD (OR 3.37[2.57,4.43]), hypertension (OR 2.68[2.11,3.41]), DM (OR 1.60[1.31,1.95]) and male sex (OR 1.31[1.21,1.42]), findings that were mostly conserved during sub-analysis of studies stratified into four global geographic regions.

55 Conclusions: Age, chronic respiratory illness, CVD, hypertension, DM and male sex may represent prognostic
56 factors for the development of both acute and chronic cardiovascular complications in COVID-19 disease,
57 highlighting the need for a multidisciplinary approach to chronic disease patient management.

- 58
- 59
- 60

It is made available under a CC-BY-NC-ND 4.0 International license .

62 INTRODUCTION

63 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged at the end of 2019 and has since gone 64 on to cause the ongoing coronavirus disease 2019 (COVID-19) pandemic, infecting >50 million people 65 worldwide. SARS-CoV-2 causes a broad range of respiratory symptoms, ranging from subclinical disease to 66 viral pneumonia [1]. However, it is increasingly apparent that SARS-CoV-2 also causes a variety of extra-67 respiratory complications [1]. Specifically, SARS-CoV-2 infection has been associated with acute myocardial 68 injury, myocarditis, arrhythmias, venous thromboembolism and other cardiac complications [2-6]. The 69 development of these complications is likely enhanced by experimental testing of antimalarial and antiviral 70 drugs, which have known cardiovascular side effects [4-12]. Although prevalence estimates vary, data from 71 China suggests that approximately 7% of patients infected with SARS-CoV-2 develop cardiac injury (defined as 72 elevated high-sensitivity cardiac troponin I or new echocardiographic; electrocardiographic (ECG) 73 abnormalities) [13]. This prevalence increases to 25% in those hospitalised with COVID-19 [14], and 22% in 74 patients who required intensive care unit (ICU) admission [13]. However, at present, the role of pre-existing 75 chronic disease in the cardiac complications of COVID-19 remains to be elucidated.

76

77 Pre-existing chronic respiratory disease, cardiovascular disease (CVD), hypertension and diabetes mellitus 78 (DM) have each been associated with increased rates of hospitalization, ICU admission, and death from the 79 respiratory complications of SARS-CoV-2 [13–27]. It is not yet well defined whether these patient groups are 80 also at an increased risk of SARS-CoV-2 associated cardiac injury. Some small studies have shown that patients 81 with pre-existing CVD are at a higher risk of myocarditis and/or myocardial infarction (MI) from SARS-CoV-2 82 [3, 28, 29]. A retrospective, single-centre case series of 187 patients with COVID-19 also found that pre-83 existing CVD increased the risk of cardiac injury (as defined by troponin elevation) (54.5% vs 13.2%) and 84 mortality compared with patients without CVD [3]. Similarly, a meta-analysis of 28 observational studies found 85 SARS-CoV-2 associated cardiac injury biomarkers to be related to a history of hypertension but not DM [30]. In 86 contrast, Zhu and colleagues found that individuals with type 2 DM had a greater occurrence of acute heart 87 injury (7.3% versus 3.0%) than individuals without DM [31].

88 There is a clear need to better understand the role of patient host factors in the extra-respiratory complications of 89 SARS-CoV-2 infection. Here, we analysed the currently available literature on the role of pre-existing chronic

90 respiratory illnesses, CVD, hypertension and DM in the prevalence of SARS-CoV-2 associated cardiac injury.

- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 70
- 99

It is made available under a CC-BY-NC-ND 4.0 International license .

100 METHODS

101

102 Study selection

103 We retrospectively investigated published and pre-printed, publicly released and de-identified data made 104 available between Dec 1, 2019, and October 14, 2020. Information was accessed from four databases (PubMed, 105 Embase, medRxiv and SSRN) using the following search terms: ("covid-19"[All Fields]) OR ("SARS-CoV-106 2"[All Fields]) AND ("cardiac"[All Fields] AND "comorbid*"[All Fields]). A total of 1076 articles were 107 retrieved after duplicates were removed (available in either English or Chinese), following which 713 records 108 were removed after screening by title and abstract. 363 full-text articles were reviewed. Of these, 283 articles 109 were excluded because i) they did not include original research, ii) they were not relevant to the outcome, iii) 110 they described an inappropriate patient population and/or iv) they described case reports of <10 patients. Of the 111 remaining 80 studies that were deemed eligible, due to their containing data on patient pre-existing disease and 112 cardiac complications as an outcome, 25 contained the required data format and these were extracted. The 113 authors of the remaining 55 studies were contacted to request appropriate data (as they presented only aggregate 114 data that did not specify the cross-over between pre-existing chronic disease and outcome), to which four groups 115 responded with data contributions. Thus, a final of 29 studies were included in the meta-analysis [3,4,29,32-57]. 116 The selection process is shown in Figure 1.

117

118 Data extraction and analysis

119 Extracted variables were aggregate data of median age, sex, underlying chronic disease (chronic respiratory 120 illness, CVD, hypertension and DM) and the occurrence of cardiac complications as an outcome. Patients with 121 co-morbidities were included in all applicable categories. For cases in which the data source reported more than 122 one type of co-morbid CVD separately (such as prevalence of both chronic heart failure and coronary heart 123 disease within their cohort), only the group with the largest number of cases was included to avoid patient 124 double up and overrepresentation of co-morbid CVD. Analyses for each co-morbidity were performed 125 independently, with each assuming one effect (the patient group in question) is considered as the main driver 126 of effects. Median data for age were analysed individually using a Mann-Whitney U test. R version 4.0.0 127 software was used to analyse sex distribution as well as pre-existing chronic disease and cardiac outcomes 128 through meta \Box analysis. Heterogeneity among studies was assessed by using the Q statistic with $*P \leq 0.05$ indicating the presence of significant heterogeneity and quantified by using the I^2 statistic. A fixed-effects 129 130 model was used as when $I^2 \square < \square 50\%$ and random-effects model when $I^2 \square > \square 50\%$.

131

134

132 Definition of cardiac complications

133 Cardiac complications were defined as one or more of the following: blood levels of cardiac biomarkers

abnormalities observed in clinical assessments of the patients' heart function, including ECG [61–65] or

(troponin I or creatine-kinase myocardial band) above the 99th percentile upper reference limit [58–60], and/or

- ability and the second of the parents from the function, metaling feet [of of
- echocardiography [62–66].
- 137

138 Quality assessment and data synthesis

It is made available under a CC-BY-NC-ND 4.0 International license .

5

139 140 141 142 143	The included studies were critically appraised using Newcastle Ottawa Quality Assessment Scale (NOS) [67]. High-quality studies were defined as studies fulfilling NOS score of minimum 7. Data were synthesised from 29 different and high-quality studies [3,4,29,32–57]. This systematic review was conducted based on the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) [68] and Meta-analysis of Observational Studies in Epidemiology (MOOSE) [69] statements.
144	
145	
146	
147	
148	
149	
150	
151	
152	
$153 \\ 154 \\ 155 \\ 156 \\ 157 \\ 158 \\ 159 \\ 160 \\ 161 \\ 162 \\ 163 \\ 164 \\ 165 \\ 166 \\ 167 \\ 168 \\ 169 \\ 170 \\ 171 \\ 171 \\ 171 \\ 100 \\ 171 \\ 100 $	
172	
173	

It is made available under a CC-BY-NC-ND 4.0 International license .

177 SARS-CoV-2 patients with pre-existing chronic illnesses are at increased risk of acute cardiac complications 178 179 We identified 1076 articles that described pre-existing chronic disease and cardiac complications of SARS-180 CoV-2, rejected 996 articles due to a lack of sufficient and/or appropriate data and derived a total of 80 articles. 181 29 of these studies were subsequently used in a meta-analysis (Figure 1), all of which were high quality (Table 182 1). Baseline characteristics of the patient populations as well as other relevant data are listed in Table 2. The 183 definition of cardiac complications varied between studies, ranging from acute cardiac injury to fulminant 184 myocarditis. 20 studies measured cardiac outcomes on the day of admission [3,29,32,34,35,37-41,43-48,50-185 52,57], and one at the time of patient death [33], with the remaining eight studies not specifying the time of 186 assessment [4,36,42,49,53-55]. The studies were conducted in 10 countries in four geographical locations 187 (U.S.A. [32,33,41,48,49], the Middle East [34,50,52], Europe [4,35-40,44,45,47], and the People's Republic of 188 China [3,29,42,43,46,51,53–57]) with a total of 3553 COVID-19 patients developing cardiac complications and 189 13,225 COVID-19 patients without cardiac complications. Patients who presented with SARS-CoV-2 associated 190 cardiac complications were, on average, 10 years older than in those who did not (Table 2). 191

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 1. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flowchart of
 study selection.

It is made available under a CC-BY-NC-ND 4.0 International license .

	Study	Selection	Comparability	Outcome	Total
	Abrams et al., 2020 ³²	****		***	7
	Arentz et al., 2020 ³³	****		***	7
	Barman et al., 2020 ³⁴	****		***	7
	Bertini et al., 2020 ³⁵	****		***	7
	CAPACITY COVID, 2020 ³⁶	****		***	7
	Duerr et al., 2020 ³⁷	****		***	7
	Ferrante et al., 2020 ³⁸	****		***	7
	Ghio et al., 2020 ³⁹	****		***	7
	Guo et al., 2020^3	****		***	7
	Lairez et al., 2020 ⁴⁰	****		***	7
	Lala et al., 2020 ⁴¹	****		***	7
	Li et al., 2020 ⁴²	****		***	7
	Liu et al., 2020 ⁴³	****		***	7
	Lombardi et al., 202044	****		***	7
	Lorente-Ros et al., 2020 ⁴⁵	****		***	7
	Ma et al., 2020 ⁴⁶	****		***	7
	Pagnesi et al., 202047	****		***	7
	Raad et al., 2020 ⁴⁸	****		***	7
	Sala et al., 2020^4	****		***	7
	Shah et al., 2020 ⁴⁹	****		***	7
	Shahrokh et al., 2020 ⁵⁰	****		***	7
	Shi et al., 2020 ²⁹	****		***	7
	Song et al., 2020 ⁵¹	****		***	7
	Szekely et al., 2020 ⁵²	****		***	7
	Toraih et al., 2020 ⁵³	****		***	7
	Wei et al., 2020 ⁵⁴	****		***	7
	Xie et al., 2020 ⁵⁵	****		***	7
	Xu G et al., 2020 ⁵⁶	****		***	7
	Xu H et al., 2020 ⁵⁷	****		***	7
16 -					

217

 $\begin{array}{c} 218\\ 219\\ 220\\ 221\\ 222\\ 223\\ 224\\ 225\\ 226\\ 227\\ 228\\ 229\\ 230\\ 231\\ 232\\ 233\\ \end{array}$

Study	Population		Sample size (males)		Age (ye	ears)	CC description	Assessment	Time of	
		СС	No CC	СС	No CC	Findings	_		assessment	
Abrams et al., 2020^{32}	Mortally ill COVID-19 patients hospitalised in 3 New York City hospitals between March 1 and April 3, 2020	11 (9)	122 (74)	64 (58- 72)	82 (71.8- 89)	<i>p</i> =0.0009	Arrhythmic death	Last recorded cardiac rhythm	After death	
Arentz et al., 2020^{33}	Critically ill COVID-19 patients admitted to Evergreen Hospital ICU, Washington State	15 (8)	6 (3)	74 (61- 82)	69.5 (66- 73)	<i>p</i> =0.3699	Cardio- myopathy	Radiologic and laboratory findings	Day of ICU admission and again on day 5	
Barman et al., 2020 ³⁴	Consecutive COVID-19 patients hospitalised in three government hospitals in Istanbul, Turkey	150 (86)	457 (248)	68.5± 13.4	56.5± 15.2	<i>p</i> <0.001	Cardiac injury	Laboratory findings only	Day of hospital admission	
Bertini et al., 2020 ³⁵	431 consecutive COVID-19 patients hospitalized in Italy between 10 March and 14 April 2020 who died or were treated with invasive mechanical ventilation.	24 (16)	86 (64)	71 (59- 76)	68 (60- 78)	<i>p</i> =0.88	Hs-TnI > 5x the upper reference limit	Laboratory findings only	Day of hospita admission	
CAPACITY COVID, 2020 ³⁶	COVID-19 patients registered to the international CAPACITY- COVID collaborative consortium with inclusion current from 13 countries	752 (537)	4811 (3019)	71 (64- 77)	66 (55- 76)	<i>p</i> <0.001	Cardiac complication	According to criteria of the European Society of Cardiology	From hospital discharge	
Duerr et al., 2020 ³⁷	COVID-19 patients admitted to the University Hospital Bonn, Germany	9 (4)	10 (5)	NA	NA	NA	Pericardial effusion	Radiologic and laboratory findings	Day of hospital admission	
Ferrante et al., 2020^{38}	Consecutive COVID-19 patients undergoing chest CT on admission to Humanitas Research Hospital in Milan, Italy	123 (95)	209 (142)	74.2 (67.8- 80.1)	60.7 (51.4- 70.5)	<i>p</i> <0.001	Myocardial injury	Radiologic and laboratory findings	Day of hospital	
Ghio et al., 2020 ³⁹	Consecutive adult COVID-19 patients admitted to the Emergency Department of Fondazione IRCCS Policlinico San Matteo (Pavia, Italy) from February 21st to March 31st 2020	74 (51)	266 (188)	76.1 (69.7- 82.5)	68.6 (56.4- 76.4)	<i>p</i> <0.001	Myocardial injury	Laboratory findings only	Day of hospital admission	
Guo et al., 2020^3	Consecutive COVID-19 patients admitted to the Seventh Hospital of Wuhan City, China	52 (34)	135 (57)	71.4 (SD= 9.43)	53.53 (SD= 13.22	<i>p</i> <0.001	Myocardial injury	Laboratory findings only	Day of hospital admission	

)				
Lairez et al., 2020 ⁴⁰	COVID-19 patients admitted to Rangueil Hospital of Toulouse University for dyspnea or chest pain from April 6, 2020, to May 1, 2020.	13 (11)	18 (16)	66±8	52±1 3	<i>p</i> =0.015	Myocardial injury	Radiologic and laboratory findings	Day of hospital admission
Lala et al., 2020 ⁴¹	COVID-19 patients admitted to five Mount Sinai Health System hospitals in New York City	530 (318)	2206 (1312)	Medi an=7 0-80	Medi an=6 0-70	NA	Myocardial injury	Laboratory findings only	Day of hospital admission
Li et al., 2020 ⁴²	Critical type COVID-19 patients randomly selected from Renmin Hospital of Wuhan University, China	34 (23)	48 (29)	70.59 % >70	37.5 % >70	<i>p</i> =0.003	Myocardial damage	Laboratory findings only	NA It is ma
Liu et al., 2020 ⁴³	COVID-19 patients from Shenzhen Third People's Hospital in Shenzhen, China	1 (1)	11 (7)	63	62 (36- 65)	NA	Fulminant myocarditis, cardiac failure	Radiologic and laboratory findings	Day of hospita
Lombardi et al., 2020 ⁴⁴	Consecutive COVID-19 patients hospitalized in 13 Italian cardiology units from March 1 to April 9, 2020.	278 (201)	336 (234)	71.3 (12)	64.0 (13.6)	<i>p</i> <0.001	Myocardial injury	Laboratory findings only	ਰ Day of hospita admission ਕੂ
Lorente-Ros et al., 2020 ⁴⁵	Consecutive adult COVID-19 patients admitted to a large tertiary hospital in Madrid, Spain	148 (71)	559 (193)	78.7	63.4	Standardis ed difference = 114%	Myocardial injury	Laboratory findings only	ھ Day of hospital admission
Ma et al., 2020 ⁴⁶	Adult patients hospitalised with COVID-19 in Yongchuan, Chongqing, China	45 (27)	39 (21)	51 (45.5- 63.5)	45 (39- 53)	<i>p</i> =0.026	NA	Radiologic and laboratory findings	Day of hospitation
Pagnesi et al., 2020 ⁴⁷	Hospitalised non-ICU COVID-19 patients from a large tertiary centre in Milan, Italy	29 (20)	171 (111)	65 (55- 76)	62 (54- 74)	<i>p</i> =0.813	Right ventricular dysfunction	Radiologic and laboratory findings	Day of hospitation
Raad et al., 2020 ⁴⁸	COVID-19 patients admitted to Henry Ford Health System in Southeast Michigan, USA, between March 9 and April 15, 2020.	390 (229)	630 (280)	70 (51- 89)	59 (39- 79)	NA	Cardiac injury	Laboratory findings only	Day of hospita
Sala et al., 2020^4	Non-ICU COVID-19 patients admitted to seven COVID-19 units at a third-level hub centre in Milan, Italy	12 (NA)	116 (NA)	73±1 0	64±1 4	NA	Arrhythmias	Radiologic findings only	NA .
Shah et al., 2020^{49}	Covid-19 patients admitted to 3 Phoebe Putney hospitals in Southwest Georgia, USA, between March 2 and June 7, 2020.	116 (62)	193 (70)	68.2± 14.1	59.9± 14.0	<i>p</i> <0.001	Cardiac injury	Laboratory findings only	NA
Shahrokh et al., 2020 ⁵⁰	COVID-19 patients presenting to the Sina Hospital emergency department in south Tehran, Iran between March and May 2020.	115 (69)	271 (167)	64.98 ±15.2 9	57.12 ±15.4 8	<i>p</i> <0.001	Cardiac injury	Radiologic and laboratory findings	Day of hospital admission
Shi et al.,	Consecutive severe COVID-19 inpatients of Renmin Hospital,	106	565	73	57	<i>p</i> <0.001	Myocardial	Laboratory	Day of hospital

2020 ²⁹	Wuhan University, China	(58)	(264)	(66- 80)	(43- 70)		injury	findings only	admission
Song et al., 2020^{51} Szekely et al., 2020^{52}	Critically ill COVID-19 patients admitted to the ICU at Tongji Hospital, Wuhan, China Consecutive adult COVID-19 patients admitted to Tel Aviv Medical Center, Israel	34 (24) 68 (46)	30 (18) 32 (17)	67.8± 10.3 69.8± 16	61.3± 13.3 65.9± 20	<i>p</i> =0.033 <i>p</i> =0.56	Myocardial injury Abnormal echocardiogram	Laboratory findings only Radiologic findings only	Day of hospital admission Day of admission
Torah et al., 2020^{53}	cOVID-19 patients included in studies exploring pre-existing CVD as COVID-19 risk factors, cardiac injury, ICU admission or mortality	202 (NA)	958 (NA)	NA	NA	NA	Cardiac injury	Laboratory findings only	NA =
Wei et al., 2020 ⁵⁴	COVID-19 patients admitted to two treatment centres in Sichuan, China	16 (7)	85 (47)	67(61 -80.5)	47(33 -55)	<i>p</i> <0.001	Acute myocardial injury	Radiologic and laboratory findings	NA ade a
Xie et al., 2020 ⁵⁵	Non-critically ill COVID-19 patients admitted to Tongji Hospital, Wuhanm China	102 (46)	517 (251)	68.9± 11.7	56.4± 13.6	<i>p</i> <0.001	Acute cardiac- related injury	Radiologic and laboratory findings	NA ^{Vailable}
Xu G et al., 2020 ⁵⁶	Adult patients with COVID-19 in Guangzhou, China	12 (6)	253 (116)	62.6± 14.5	48.1± 15.5	<i>p</i> =0.002	Acute cardiac injury	Radiologic and laboratory findings	NA er a O
Xu H et al., 2020 ⁵⁷	COVID-19 patients consecutively hospitalized between January 2 and March 17, 2020, in the Public Health Clinical Center of Chengdu, China.	47 (23)	46 (23)	41 (31- 51)	54 (40- 65)	<i>p</i> <0.001	Cardiac marker abnormalities	Laboratory findings only	Day of hospitak admission Z
CC: cardiac cor 235	nplications; ICU: intensive care unit; NA: data not available.								D 4.0 II
236									nternati
237									ional li
238									cense.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.21.20136622; this version posted December 10, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 240
 In a pooled analysis, chronic respiratory illness (odds ratio (OR): 1.67, 95% confidence interval (CI)

 241
 [1.48,1.88]) (Fig. 2), CVD (OR: 3.37, 95% CI [2.57,4.43]) (Fig. 3), hypertension (OR: 2.68, 95% CI
- 242 [2.11,3.41]) (Fig. 4), DM (OR: 1.60, 95% CI [1.31,1.95]) (Fig. 5), and male sex (OR: 1.31, 95% CI [1.21,1.42])
- 243 (Fig. 6), were each associated with a higher incidence of SARS-CoV-2 associated cardiac complications.



Figure 2: Forest plot of chronic respiratory illness as a risk factor for cardiac complications in COVID-19 patients. Fixed effect models apply when $I^2 < 50\%$.

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 3: Forest plot of pre-existing cardiovascular disease as a risk factor for cardiac complications in COVID-

261 19 patients. Random effect models apply when $I^2 > 50\%$.

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 4: Forest plot of hypertension as a risk factor for cardiac complications in COVID-19 patients. Random effect models apply when $I^2 > 50\%$.

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 5: Forest plot of diabetes mellitus as a risk factor for cardiac complications in COVID-19 patients. Random effect models apply when $I^2 > 50\%$.

It is made available under a CC-BY-NC-ND 4.0 International license .



285 286 Figure 6: Forest plot of male sex as a risk factor for cardiac complications in COVID-19 patients. Fixed effect 287 models apply when $l^2 < 50\%$.

288

As large heterogeneity was detected amongst the total combined study cohort, the cohort was subdivided based on general global region in an attempt to account for this. Cohorts were divided into studies with cohorts primarily situated in the U.S.A [32,33,41,48,49], the Middle East [34,50,52], Europe [4,35–40,44,45,47], and China [3,29,42,43,46,51,53–57].

293

294 Regionally-pooled sub-analysis of chronic respiratory illness found it to be associated with a higher incidence of

SARS-CoV-2 associated cardiac complications in cohorts from the U.S.A. (OR: 1.64, 95% CI [1.28,2.09]) (Fig.

296 7, A), Europe (OR: 1.53, 95% CI [1.28,1.83]) (Fig. 7, C) and China (OR: 1.94, 95% CI [1.49,2.52]) (Fig. 7, D),

but not the Middle East (Fig. 7, B). Regional subdivision accounted for the high heterogeneity amongst all but

the Middle Eastern cohort.

It is made available under a CC-BY-NC-ND 4.0 International license .





305

306 Regionally-pooled sub-analysis of pre-existing CVD found its association with a higher incidence of SARS-

- 307 CoV-2 associated cardiac complications to be conserved across all cohorts from the U.S.A. (OR: 3.55, 95% CI
- 308 [2.51,5.04]) (Fig. 8, A), the Middle East (OR: 2.40, 95% CI [1.25,4.62]) (Fig. 8, B), Europe (OR: 2.99, 95% CI
- 309 [1.90,4.69]) (Fig. 8, C), and China (OR: 5.52, 95% CI [3.88,7.85]) (Fig. 8, D), despite regional subdivision
- 310 failing to account for high heterogeneity amongst the former three regions.
- 311

It is made available under a CC-BY-NC-ND 4.0 International license .



312 313

Figure 8: Forest plots of pre-existing cardiovascular disease as a risk factor for cardiac complications in 314 COVID-19 patients divided by geographical region. A | Studies based primarily in the United States of America. 315 B | Studies based primarily around the Middle East. C | Studies based primarily in Europe. D | Studies based 316 primarily in China. Fixed effect models apply when $l^2 < 50\%$ and random effects models apply when $l^2 > 50\%$.

- 317
- 318

319 Regionally-pooled sub-analysis of hypertension found its association with a higher incidence of SARS-CoV-2 320 associated cardiac complications to be similarly conserved across all cohorts from the U.S.A. (OR: 2.23, 95% 321 CI [1.22,4.08]) (Fig. 9, A), the Middle East (OR: 2.24, 95% CI [1.70,2.94]) (Fig. 9, B), Europe (OR: 2.38, 95% 322 CI [1.46,3.88]) (Fig. 9, C), and China (OR: 3.94, 95% CI [3.10,5.01]) (Fig. 9, D), although regional subdivision 323 could not account for high heterogeneity amongst the American and European cohorts.

It is made available under a CC-BY-NC-ND 4.0 International license .

Abrams et al., 2020 Arentz et al., 2020 Lala et al., 2020 Raad et al., 2020 Shah et al., 2020 Total (fixed effect) Total (random effects) Heterogeneity: $\chi_4^2 = 23.07$	0.7 (95% C) 0.24 (0.05; 1.05] 24.00 (2.04; 282.67] 1.76 (1.45; 2.13] 3.16 (2.28; 4.37] 3.53 (1.59; 7.84] 2.11 (1.81; 2.48] 2.23 (1.22; 4.08] (P < .001), I ² = 83%	0.01	0.1 1 10 1 Odds Ratio (95% Cl)
В			
Source Barman et al., 2020 Shahrokh et al., 2020 Szekely et al., 2020 Total (fixed effect) Total (random effects Heterogeneity: $\chi^2_2 = 0.2^{10}$	OR (95% Cl) 2.22 [1.53; 3.24] 2.39 [1.53; 3.73] 1.83 [0.78; 4.28] 2.24 [1.70; 2.94] 9 (<i>P</i> = .86), <i>I</i> ² = 0%	,	0.5 1 2 Odds Ratio (95% Cl)
C Source	OR (95% CI)		
Duerr et al., 2020	5.00 [0.66; 38.15]		
Ferrante et al., 2020	4.43 [2.70; 7.28]		· · · ·
Lairez et al., 2020	8.67 [1.66; 45.21]		1
Lombardi et al., 2020	1.90 [1.37; 2.63]		
Pagnesi et al., 202	0 82 [0 37 1 84]		
Sala et al., 2020	1.83 [0.55; 6.10]		
Total (fixed effect)	1.72 [1.52; 1.94]		•
Total (random effects)	2.38 [1.46; 3.88]	1	
Heterogeneity: $\chi_7 = 50.63$	P < .001, $T = 86%$	0	1 05 1 2 10
_			Odds Ratio (95% CI)
D Source	OR (95% CI)		
Guo et al., 2020	6.64 [3.29; 13.38]		+
Li et al., 2020	2.38 [0.97; 5.85]		
Liu et al., 2020	0.81 [0.03; 25.10]		•
Ma et al., 2020	3.00 [0.75; 12.00]		
Shi et al., 2020 Song et al., 2020	4.62 [3.00; 7.13]		
Toraib et al., 2020	2.40 [0.67, 0.57]		
Weietal 2020	7 82 [2 45 24 98]		
Xie et al 2020	3 52 [2 27: 5 45]		
Xu G et al., 2020	2.97 [0.91: 9.77]		
Xu H et al., 2020	3.57 [0.90; 14.15]		
T-t-1 (E	3.94 [3.10; 5.01]		\$
l otal (fixed effect)	1 2 00 12 42. E 0C1		\diamond
Total (fixed effect)	3.98 [3.13, 5.06]		
Total (fixed effect) Total (random effects Heterogeneity: χ_9^2 = 7.5	$8 (P = .58), I^2 = 0\%$		

325 326 ac complications in COVID-19 patients divided 327 by geographical region. A | Studies based primarily in the United States of America. B | Studies based primarily 328 around the Middle East. C | Studies based primarily in Europe. D | Studies based primarily in China. Fixed 329 effect models apply when $I^2 < 50\%$ and random effects models apply when $I^2 > 50\%$.

- 330
- 331

332 The association between DM and a higher incidence of SARS-CoV-2 associated cardiac complications was also 333 conserved across all cohorts from the U.S.A. (OR: 1.54, 95% CI [1.32,1.78]) (Fig. 10, A), the Middle East (OR: 334 1.65, 95% CI [1.25,2.19]) (Fig. 10, B), Europe (OR: 1.50, 95% CI [1.07,2.09]) (Fig. 10, C), and China (OR: 335 2.04, 95% CI [1.13,3.70]) (Fig. 10, D), despite regional subdivision not accounting for high heterogeneity

- 336 amongst the European and Chinese cohorts.
- 337



338 339 Figure 10: Forest plots of diabetes mellitus as a risk factor for cardiac complications in COVID-19 patients 340 divided by geographical region. A | Studies based primarily in the United States of America. B | Studies based 341 primarily around the Middle East. C | Studies based primarily in Europe. D | Studies based primarily in China. 342 Fixed effect models apply when $I^2 < 50\%$ and random effects models apply when $I^2 > 50\%$.

- 343
- 344
- 345 Finally, regionally-pooled sub-analysis of male sex found it to be associated with a higher incidence of SARS-
- 346 CoV-2 associated cardiac complications in cohorts from the U.S.A. (OR: 1.55, 95% CI [1.03,2.33]) (Fig. 11, A),
- 347 and Europe (OR: 1.40, 95% CI [1.23,1.59]) (Fig. 11, C), but not the Middle East (Fig. 11, B) or China (Fig. 11,
- 348 D). Regional subdivision accounted for the high heterogeneity amongst all but the American cohort.
- 349



Figure 11: Forest plots of male sex as a risk factor for cardiac complications in COVID-19 patients divided by geographical region. A | Studies based primarily in the United States of America. B | Studies based primarily around the Middle East. C | Studies based primarily in Europe. D | Studies based primarily in China. Fixed effect models apply when $I^2 < 50\%$ and random effects models apply when $I^2 > 50\%$.

It is made available under a CC-BY-NC-ND 4.0 International license .

365 **DISCUSSION**

366

Our meta-analysis shows that older age, male sex, and pre-existing chronic respiratory disease, CVD, hypertension and DM are all risk factors for the development of cardiac complications associated with SARS-CoV-2 infection. At present the reasons for each of these association are unclear; each is a respiratory risk factor and thus might cause an indirect cardiac effect, however it could equally be the case that they exert their own direct catalytic effect on cardiac complications.

372

Our analysis identified a significant association between pre-existing CVD and the risk of SARS-CoV-2 associated cardiac complications, which was conserved across global geographical regions. This is consistent with previous observations that 30% of patients with SARS-CoV-2 cardiac injury had a history of coronary heart disease [3,29]. The reason for this association remains unclear. These data may be the result of preexisting CVD leading to an altered immune response, excessive cytokine release [5], endothelial dysfunction, increased procoagulant blood activity, rupturing of coronary atherosclerotic plaques [73], and the formation of an occlusive thrombi [74].However, further investigations are required to validate this hypothesis.

380

381 The meta-analysis performed herein also found that chronic respiratory illness significantly increased the 382 incidence of SARS-CoV-2 associated cardiac complications. It is possible that these data reflect the established 383 indirect association between severe respiratory disease and subsequent acute cardiovascular event Indeed, 384 COVID-19 patients with pneumonia and acute respiratory distress syndrome (ARDS) display acute right 385 ventricular hypertrophy despite an absence of pulmonary embolism or severe pulmonary hypertension [87]. 386 However, chronic lung disease has not been consistently associated with SARS-CoV-2 ARDS and hypoxemia 387 [88], and thus this is unlikely to be the sole explanation for the increased risk of cardiac complications in 388 patients with chronic respiratory illness in the present analysis. SARS-CoV-2 associated cardiac complications

389

390 The association between underlying DM and cardiac complications from SARS-CoV-2 may be attributable to a 391 multitude of other effects induced by abnormal circulating substrates, including hyperglycaemia, and/or the co-392 existence and complex interactions with other, even subclinical, conditions in this patient group [91]. In 393 response to changes in substrate availability, for example, the diabetic heart becomes increasingly dependent on 394 fatty acids as a fuel source, which decreases work efficiency, and dysregulates responses to hypoxia [92]. These 395 metabolic changes may predispose individuals with DM to an increased risk of ischemic cardiac injury upon 396 SARS-CoV-2 infection. The contribution of underlying DM to the risk of SARS-CoV-2 associated cardiac 397 complications, however, depends largely on the duration of pre-existing disease [93].

- 398
- 399

There are several limitations in our review. Firstly, the limited number of studies that met the pre-defined selection criteria disallowed correction for other variables that may confound these results. For example, it is possible that our observations were confounded by the strong effect that age has on cardiovascular health. Thus, it is not possible to conclude if people with these pre-existing conditions are just more susceptible to severe COVID-19 and thus the heart complications associated with this increased severity, or if there is indeed a

It is made available under a CC-BY-NC-ND 4.0 International license .

23

405 cardiac-specific effect occurring. Similarly, we cannot exclude the possibility that the associations observed 406 herein are due, at least in part, to treatments for severe COVID-19 that may damage the heart. Indeed, the 407 experimental therapeutic hydroxychloroquine has been associated with QT interval prolongation, 408 cardiomyopathy and heart failure [8–10]. This is likewise the case for treatments for underlying conditions, such 409 as ACE inhibitors and ARBs which, while not known to damage the heart, may interfere with how the immune 410 system targets the virus [78]. Information regarding which, if any, therapeutics used in these cohorts of patients 411 was not consistently available. We anticipate that as more data on the cardiac complications become available it 412 will be possible for future analyses to correct for these and other confounders; however, it would also be 413 worthwhile testing the effects of each these pre-existing chronic conditions in one of the recently developed 414 murine models of SARS-CoV-2. 415 416 Despite the above limitations, these data have important implications for patient care. Patients with one or more 417 underlying medical conditions should be closely monitored for both severe respiratory and extra-respiratory 418 COVID-19 complications. Furthermore, the exploratory use of medications that are independently associated 419 with cardiac complications should be considered with caution in these patient groups and perhaps bypassed in 420 favour of lower-risk treatment options. There is thus a clear need for a multidisciplinary, collaborative team to 421

- 422
- 423 **RESOURCE AVAILABILITY**
- 424

425 Lead contact: Further information and requests for resources should be directed to and will be fulfilled by the 426 Lead Contact, Dr. Kirsty Short (k.short@uq.edu.au).

manage the complexity of COVID-19 illness observed in patients with one or more underlying chronic disease.

427

428 Materials availability: This study did not generate new unique reagents.

429

430 Data and code availability: All data relevant to this study has been included in the manuscript. Data 431 contributed by Xu et al., 2020^{31} , Ma et al., 2020^{32} , and Arentz et al., 2020^{35} , may be obtained by contacting 432 authors of each respective study. Data retrieved from remaining studies are published and publicly available. R 433 version 4.0.0 software was used to analyse sex distribution as well as pre-existing chronic disease and cardiac 434 outcomes through meta analysis. The datasets/code supporting the current study have not been deposited in a 435 public repository but are available from the corresponding author on request.

- 436
- 437
- 438
- 439
- 440
- 441
- 442
- 443

It is made available under a CC-BY-NC-ND 4.0 International license .

24

444

445 **DECLARATIONS**

446

447 Acknowledgements: We want express our gratitude to the CAPACITY-COVID collaborative 448 consortium for their data contribution: 449 Admiraal de Ruyter Hospital, Goes, the Netherlands: van Kesteren HAM 450 452 452 453 455 455 455 457 89 Albert Schweitzer Hospital, Dordrecht, the Netherlands: van de Watering DJ Amphia Hospital, Breda, the Netherlands: Schaap J, Alings AMW Amstelland Hospital, Amstelveen, the Netherlands: Asselbergs Koning AMH Amsterdam University Medical Center, Amsterdam, the Netherlands: Pinto Y, Tjong FVY Antonius Hospital, Sneek, the Netherlands: de Vries JK Antwerp University Hospital, Antwerp, Belgium: van Craenenbroeck EM, Kwakkel – van Erp HM, van Ierssel S AZ Maria Middelares, Gent, Belgium: de Sutter J Barts Health NHS Trust, London, United Kingdom: Saxena M Beatrix Hospital, Gorinchem, the Netherlands: Westendorp PHM Bernhoven Hospital, Uden, the Netherlands: van de Wal RMA 460 Bravis Hospital, Roosendaal, the Netherlands; Dorman HGR, van Boxem AIM 461 462 463 Catharina Hospital, Eindhoven, the Netherlands: Tio RA CHU UCL Namur - Site Godinne, Yvoir, Belgium: Gabriel LG Deventer Hospital, Deventer, the Netherlands: Badings EA 464 Diakonessenhuis, Utrecht, the Netherlands: van Ofwegen-Hanekamp CEE Dijklander Hospital, Hoorn, the Netherlands: Wierda E 466 467 468 Dutch Network for Cardiovascular Research (WCN): Schut A $Elizabeth\-TweeSteden\-Hospital,\-Tilburg,\-the\-Netherlands:\-Monraats\-PS$ E.M.M.S Hospital, Nazareth, Israel: Hellou EH 469 470 472 473 475 475 475 477 477 8 478 479 0 Erasmus University Medical Center, Rotterdam, the Netherlands: den Uil CA, Jewbali LS Fransiscus Gasthuis, Rotterdam, the Netherlands: Nierop PR Fransiscus Vlietland, Schiedam, the Netherlands van der Linden MMJM Gelre Hospitals, Apeldoorn, the Netherlands: Groenemeijer BE Gelre Hospitals, Zutphen, the Netherlands: Al-Windy NYY Groene Hart Hospital, Gouda, the Netherlands: van Hessen MWJ Haaglanden Medical Center, den Haag, the Netherlands: van der Heijden DJ Hospital do Espirito Santo, Évora, Portugal: Ribeiro MIA Hospital Group Twente, Almelo, the Netherlands: Linssen GCM Hospital Prof. Doutor Fernando Fonesca, Amadora, Portugal: Ferreira JB Imperial College Healthcare NHS Trust, London, United Kingdom: Prasad S I.M. Sechenov First Moscow State Medical University, Moscow, Russia: Kopylov Ph. Yu., Blagova OV 481 482 483 Ikazia Hospital, Rotterdam, the Netherlands: Emans ME Incliva Research Institute, University of Valencia, Valencia, Spain: Redón J, Forner MJ Isala, Zwolle, the Netherlands: Hermanides RS 484Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands: Haerkens-Arends HE **4**85 Jessa Hospital, Hasselt, the Netherlands: Timmermans P Jr, Messiaen P 486 487 Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands, van Smeden M King Fahd Hospital of the University, Khobar, Saudi Arabia: Al-Ali AK, Al-Muhanna FA, Al-Rubaish AM, Almubarak YA, Alnafie AN, 488 489 Alshahrani M, Alshehri A LangeLand Hospital, Zoetermeer, the Netherlands: van der Meer P **4**90 Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom: Kearney M 490 491 492 493 Leeuwarden Medical Center, Leeuwarden, the Netherlands: van den Brink FS Leiden University Medical Center, Leiden, the Netherlands: Siebelink HJ Maasstad Hospital, Rotterdam, the Netherlands: Smits PC 494 495 496 497 Maastricht University Medical Center, Maastricht, the Netherlands: Heymans SRB Manchester University NHS Foundation Trust, Manchester, United Kingdom: Buch M Martini Hospital, Groningen, the Netherlands: Tieleman RG, Reidinga AC Meander Medical Center, Amersfoort, the Netherlands: Mosterd A **4**98 Medisch Spectrum Twente, Enschede, the Netherlands: Meijs MFL, Delsing CE, van Veen HPAA 499 Netherlands Heart Institute, Utrecht, the Netherlands: Hermans-van Ast W, Iperen EPA Northumbria Healthcare NHS Foundation Trust, Cramlington, United Kingdom: Aujayeb A One Day Surgery Hospital, Cairo, Egypt: Salah R Queen Elizabeth University Hospital, Glasgow, United Kingdom: Touyz R Rijnstate Hospital, Arnhem, the Netherlands: Seelig J Rode Kruis Hospital, Beverwijk, the Netherlands Westendorp ICD, Veldhuis LI Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom: Prasad S 506 Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom: Shore AC 507 508 509 Royal Free London NHS Foundation Trust, London, United Kingdom: Captur G Salford Royal NHS Foundation Trust, Salford, United Kingdom: Dark P San Luigi Gonzaga University Hospital, Orbassano, Turin, Italy: Montagna LM, Bianco MB, Mazzilli SGM 510 511 Saxenburgh Medical Center, Hardenberg, the Netherlands: Kaplan R, Drost JT Slingeland Hospital, Doetinchem, the Netherlands: Schellings DAAM

It is made available under a CC-BY-NC-ND 4.0 International license .

- Southern Health and Social Care Trust, Portadown, United Kingdom: Moriarty A
- Spaarne Gasthuis, Haarlem, the Netherlands: Kuijper AFM
- SSR Val Rosay, Saint-Didier-au-Mont-d'Or, France: Charlotte NC
- St. Antonius Hospital, Nieuwegein, the Netherlands: ten Berg JM
- St. Jansdal, Harderwijk, the Netherlands: van der Zee PM
- Tehran Heart Center, Tehran, Iran: Shafiee A, Hedayat B, Poorhosseini H, Saneei E The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom: Zaman A
- Treant Zorggroep, Hoogeveen, the Netherlands: Anthonio RL
- University College London Hospitals NHS Foundation Trust, London, United Kingdom: Williams B. Patel R. Bell R
- University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom: Caputo M
- University Hospital Brussels, Brussels, Belgium: Weytjens C
- University Hospital Complex of Granada, Granada, Spain: Macías-Ruiz R
- University Hospital of Geneva, Geneva, Switzerland: Tessitore E
- University Hospitals of Leicester NHS Trust, Leicester, United Kingdom: McCann GP
- University Medical Center Groningen, Groningen, the Netherlands: van Gilst WH
- University Medical Center Utrecht, Utrecht, the Netherlands: Asselbergs FW, van der Harst P, Linschoten M
- Van Weel-Bethesda Hospital, Dirksland, the Netherlands: Wu KW
- Zaans Medical Center, Zaandam, the Netherlands: Verschure DO
- Zuyderland Medical Center, Heerlen, the Netherlands: Kietselaer BLJH 531
- 532 Author contributions: Idea and study design: KRS, LAG; Data collection and analysis: JES, YZ, GX, WM, 533
- HS, K-LM, C-FC, L-XK, K-QW, JL, MA, KRS; Writing the article: JES, KRS; Draft revision: JES, GX, WM, 534
- HS, K-LM, C-FC, L-XK, K-QW, JL, MA, MR, LAG, KRS; All authors have read the manuscript and have
- 535 approved this submission.
- 536 Declaration of interests: The authors declare no conflict of interest. The funders had no role in the design of
- 537 the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision
- 538 to publish the results.
- 539 Funding: KRS was supported by the Australian Research Council [DE180100512]. Collection of data
- 540 contributed by Xu et al. was supported by the Guangzhou Health Research Project, the Guangzhou Health
- 541 Committee (NO.20191A010014).
- 542 Ethics approval and consent to participate: The meta-analysis portion of this project was reviewed by the
- 543 Human Ethics Research Office, The University of Queensland (CRICOS provider number: 00025B; application
- 544 number: 2020001352) and deemed to be exempt from ethics review under the National Statement on Ethical
- 545 Conduct in Human Research (National Statement §5.1.22).

546 REFERENCES

- 547
- 548 1. Clerkin KJ, Fried JA, Raikhelkar J et al. COVID-19 and cardiovascular disease. Circulation. 549 2020;141:1648-1655. doi:10.1161/CIRCULATIONAHA.120.046941.
- 550 2. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, 551 China. Lancet. 2020;395:497-506. doi:10.1016/S0140-6736(20)30183-5.
- 552 3. Guo T, Fan Y, Chen M et al. Cardiovascular implications of fatal outcomes of patients with coronavirus 553 disease 2019 (COVID-19). JAMA Cardiol. 2020; doi:10.1001/jamacardio.2020.1017.
- 554 Sala S, Peretto G, Gramegna M et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a 4. 555 SARS-CoV-2 respiratory infection. Eur Heart J. 2020;41(19):1861-1862. patient with 556 doi:10.1093/eurheartj/ehaa286.
- 557 5. Zheng Y, Ma Y, Zhang J, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17:259-558 260. doi:10.1038/s41569-020-0360-5.
- 559 Inciardi RM, Lip L, Zaccone G et al. Cardiac involvement in a patient with coronavirus disease 2019 6. 560 (COVID-19). JAMA Cardiol. 2002; doi:10.1001/jamacardio.2020.1096.

- 561 7. Edelson DP, Sasson C, Chan PS, et al. Interim guidance for basic and advanced life support in adults, children, and neonates with suspected or confirmed COVID-19: from the Emergency Cardiovascular Care Committee and Get With the Guidelines® -Resuscitation Adult and Pediatric Task Forces of the American Heart Association in collaboration with the American Academy of Pediatrics, American Association for Respiratory Care, American College of Emergency Physicians, the Society of Critical Care Anesthesiologists: supporting organisations: American Association of Critical Care Nurses and National EMS Physicians. Circulation. 2020; doi:10.1161/CIRCULATIONAHA.120.047463.
- 8. Page RL, 2nd, O'Bryant CL, Cheng D et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016;134(6):e32-69. doi:10.1161/cir.00000000000426.
- 571
 9. Guzik TJ, Mohiddin SA, Dimarco A et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020; doi:10.1093/cvr/cvaa106.
- 573 10. Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers Y-M. Cardiac complications attributed to chloroquine
 574 and hydroxychloroquine: a systematic review of the literature. Drug Saf. 2018;41(10):919-931.
 575 doi:10.1007/s40264-018-0689-4.
- 576 11. Castagné B, Viprey M, Martin J, Schott A-M, Cucherat M, Soubrier M. Cardiovascular safety of tocilizumab: a systematic review and network meta-analysis. PLoS ONE. 2019; doi:10.1371/journal.pone.0220178.
- 579
 12. Corrales-Medina VF, Alvarez KN, Weissfeld LA et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;313(3):264-274. doi:10.1001/jama.2014.18229.
- 581 13. Wang D, Hu B, Hu C et al. Clinical characteristics of 138 hospitalised patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069. doi:10.1001/jama.2020.1585.
- 584
 14. Giustino G., Croft L.B., Stefanini G.G. Characterization of myocardial injury in patients with COVID-19. J Am Coll Cardiol. 2020;76:2043–2055.
- 586
 15. Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease
 2019 (COVID-19). Respir Med. 2020; doi:10.1016/j.rmed.2020.105941.
- Li B, Yang J, Zhao F et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109:521-538. doi:10.1007/s00392-020-01626-9.
- 590
 17. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3.
- 18. Yang J, Zheng Y, Gou X et al. Prevalence of comorbidities and its effects in patients infected with SARSCoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-95.
 doi:10.1016/j.ijid.2020.03.017.
- 596
 19. Chen N, Zhou M, Dong X et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. doi:10.1016/S0140-6736(20)30211-7.
- 599 20. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus disease (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi 2020;41(2):145-151. doi:10.3760/cma.j.issn.0254-6450.2020.02.003.
- 403 21. Yang X, Yu Y, Xu J et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centred, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-481. doi:10.1016/S2213-2600(20)30079-5.
- 22. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242. doi:10.1001/jama.2020.2648.
- COVID-19. Diabetes Metab. 2020; doi:10.1016/j.diabet.2020.05.001
 23. Targher G, Mantovani A, Wang X-B et al. Patients with diabetes are at higher risk for severe illness from COVID-19. Diabetes Metab. 2020; doi:10.1016/j.diabet.2020.05.001
- Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. doi:10.1016/S2213-2600(20)30116-8.
- 613 25. Wu C, Chen X, Cai Y et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020; doi:10.1001/jamainternmed.2020.0994.
- Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846-848.

618		doi:10.1007/s00134-020-05991-x.
619 620 621	27.	Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – as systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2020;14(4):395-403. doi:10.1016/j.dsx.2020.04.018.
622 623	28.	Hui H, Zhang Y, Yang X et al. Clinical and radiographic features of cardiac injury in patients with 2019 novel coronavirus pneumonia. medRxiv. 2020; doi:10.1101/2020.02.24.20027052.
624 625	29.	Shi S, Qin M, Cai Y, <i>et al.</i> Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. <i>Eur Heart J.</i> 2020; doi:10.1093/eurheartj/ehaa408.
626 627	30.	Li J-W, Han T-W, Woodward M et al. The impact of 2019 novel coronavirus on heart injury: a systematic review and meta-analysis. Prog Cardiovasc Dis. 2020; doi:10.1016/j.pcad.2020.04.008.
628 629	31.	Xhu L, She Z-G, Cheng X et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020; doi:10.1016/j.cmet.2020.04.021.
630 631	32.	Abrams M., Wan E.Y., Waase M.P., <i>et al.</i> Clinical and cardiac characteristics of COVID-19 mortalities in a diverse New York City cohort. J Cardiovasc Electrophysiol. 2020. doi: 10.1111/jce.14772.
632 633	33.	Arentz M, Yim E, Klaff L et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020;323(16):1612-1614. doi:10.1001/jama.2020.4326.
634 635	34.	Barman HA, Atici A, Sahin I, et al. Prognostic significance of cardiac injury in COVID-19 patients with and without coronary artery disease. Coronary Artery Dis. 2020; doi: 10.1097/MCA.00000000000914.
636 637 638	35.	Bertini M., Ferrari R., Guardigli G., Malagu M., Vitali F., Zucchetti O., <i>et al.</i> (2020). Electrocardiographic features of 431 consecutive, critically ill COVID-19 patients: an insight into the mechanisms of cardiac involvement <i>ESC</i> doi: 10.1093/europace/euro258
639 640	36.	Linschoten M., Asselbergs F.W. (2020). CAPACITY-COVID: a European Registry to determine the role of cardiovascular disease in the COVID-19 pandemic. doi:10.1093/eurheartj/ehaa280. The Netherlands.
641 642	37.	Accessed 13 October 2020. <u>https://capacity-covid.eu/</u> Duerr G.D., Heine A., Hamiko M., Zimmer S., Luetkens J.A., Nattermann J., <i>et al.</i> (2020). Parameters
643 644	38.	predicting COVID-19-induced myocardial injury and mortality. <i>Life Sci</i> , 260, 118400. Ferrante G., Fazzari F., Cozzi O., Maurina M., Bragato R., D'Orazio F., <i>et al.</i> (2020). Risk factors for
645 646 647	20	myocardial injury and death in patients with COVID-19: insights from a cohort study with chest computed tomography. <i>ESC</i> , doi: 10.1093/cvr/cvaa193.
648 649	39.	at presentation in patients hospitalized with COVID-19 and their outcome in a tertiary referral hospital in Northern Italy. <i>Intern Emerg Med.</i> doi: 10.1007/s11739-020-02493-v.
650 651 652	40.	Lairez O., Blanchard V., Houard V., Vardon-Bounes F., Lemasle M., Cariou E., <i>et al.</i> (2020). Cardiac imaging phenotype in patients with coronavirus disease 2019 (COVID-19): results of the cocarde study. <i>Int J Cardiovasc Imag</i> , doi: 10.1007/s10554-020-02010-4.
653 654 655	41.	Lala A., Johnson K.W., Januzzi J.L., Russak A.J., Paranjpe I., Richter F., <i>et al.</i> (2020). Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. <i>J Am College Cardiol</i> , doi: 10.1016/j.jacc.2020.06.007.
656 657 658	42. 43.	Li L., Zhang S., He B., Chen X., Zhao Q. (2020). Retrospective study of risk factors for myocardial damage in patients with critical coronavirus disease 2019 in Wuhan. <i>J Am Heart Assoc</i> , 10.1161/JAHA.120.016706. Liu Y. Yang Y. Zhang C et al. Clinical and biochemical indexes from 2019-nCov infected patients linked to
659 660	44.	viral loads and lung injury. Sci China Life Sci. 2020;63:364-374. doi:10.1007/s11427-020-1643-8. Lombardi C.M., Carubelli V., Iorio A., Inciardi R.M., Bellasi A., Canale C., <i>et al.</i> (2020). Association of
661 662		troponin levels with mortality in Italian patients hospitalized with coronavirus disease 2019: Results of a multicenter study. <i>JAMA Cardiol</i> , doi: 10.1001/jamacardio.2020.3538.
663 664 665	45.	Lorente-Ros A., Ruiz J.M.M., Rincon L.M., Perez R.O., Rivas S., Martinez-Moya R., <i>et al.</i> (2020). Myocardial injury determination improves risk stratification and predicts mortality in COVID-19 patients. <i>Cardiol J</i> , doi: 10.5603/CJ.a2020.0089.
666 667	46.	Ma K-L, Liu Z-H, Cao C-F et al. COVID-19 myocarditis and severity factors: an adult cohort study. medRxiv. 2020; doi:10.1101/2020.03.19.20034124.
668 669 670	47.	Pagnesi M., Baldetti L., Beneduce A., Calvo F., Gramegna M., Pazzanese V., <i>et al.</i> (2020). Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19. <i>Heart</i> , doi: 10.1136/heartjnl-2020-317355.
671 672 672	48.	Raad M., Dabbagh M., Gorgis S., Yan J., Chehab O., Dagher C., <i>et al.</i> (2020). Cardiac injury patterns and inpatients outcomes among patients admitted with COVID-19. <i>Elsevier</i> , doi: 10.1016/j.amiaard.2020.07.040
674 675	49.	Shah P., Doshi R., Chenna A., Owens R., Cobb A., Ivey H., <i>et al.</i> (2020). Prognostic value of elevated cardiac troponin I in hospitalized COVID-19 patients. <i>Elsevier</i> , 10.1016/j.amjcard.2020.08.041.

676 677 678	50.	Shahrokh K.S., Oraii A., Soleimani A., Hadadi A., Shajari Z., Montazeri M., <i>et al.</i> (2020). The association between cardiac injury and outcomes in hospitalised patients with COVID-19. <i>Intern Emerg Med</i> , doi: 10.1007/s11739-020-02466-1
670	51	Song V. Coo D. Don T. Oin H. Cuo E. Chang L. et al. (2020). High inflammatory hydron a potential
600	51.	Song F., Gao F., Kai F., Qiai H., Quo F., Chang E., et al. (2020). Fight inflationatory burden: a potential
601		cause of myocardial injury in critically in patients with COVID-19. Front Caralovasc Mea, doi:
001		10.5389/fcvm.2020.00128.
082	52.	Szekely Y., Lichter Y., Taleb P., Banai A., Hochstadt A., Merdler I., et al. (2020). Spectrum of cardiac
683		manifestatios in COVID-19. Circulation, 142, 342–353.
684	53.	Toraih E.A., Elshazli R.M., Hussein M.H., Elgaml A., Amin M., El-Mowafy M., et al. (2020). Association
685		of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID-19
686		patients. J Med Virol, doi: 10.1002/jmv.26166.
687	54.	Wei J-F., Huang F-Y., Xiong T-Y., Liu Q., Chen H., Wang H., et al. (2020). Acute myocardial injury is
688		common in patients with COVID-19 and impairs their prognosis. <i>Heart</i> , 106, 1154–1159.
689	55.	Xie Y., Chen S., Wang X., Li B., Zhang T., He X., <i>et al.</i> (2020). Early diagnosis and clinical significance of
690		acute cardiac injury – Under the iceberg: A retrospective cohort study of 619 non-critically ill hospitalized
691		COVID-19 pneumonia patients. <i>medRxiv</i> , doi: 10.1101/2020.07.06.20147256.
692	56	Xu G, Zhao J, Zhang F et al. Eavorable outcomes of elderly COVID-19 patients in Guangzhou. China: a
693	20.	retrospective observational study. Research Square 2020: doi:10.21203/rs.3.rs-26511/v1
601	57	$V_{\rm N}$ II How $V_{\rm N}$ N D Li Z EN II Was L at $d(2020)$. Clinical characteristics and risk factors of cardian
605	57.	Au H., Hou K., Au K., El Z., Fu H., Weit L. <i>et al.</i> (2020). Clinical characteristics and fisk factors of cardiac
095		involvement in COVID-19. J Am Heart Assoc, doi: 10.1101/JAHA.120.010807.
696	58.	Wang X, Jiang H, Wu P et al. Epidemiology of avian influenza A H7N9 virus in human beings across five
697		epidemics in mainland China, 2013-17: an epidemiological study of laboratory-confirmed case series.
698		Lancet Infect Dis. 2017;17(8):822-832. doi:10.1016/S1473-3099(17)30323-7.
699	59.	Yu D, Xiang G, Zhu W et al. The re-emergence of highly pathogenic avian influenza H7N9 viruses in
700		humans in mainland China, 2019. Euro Surveill. 2019;24(21):1900273. doi:10.2807/1560-
701		7917.ES.2019.24.21.1900273.
702	60	Thygesen K. Alpert IS. Jaffe AS et al. Fourth universal definition of myocardial infarction (2018)
703	00.	Circulation 2018-138(20):e618-651 doi:10.1161/CIR.00000000000617
704	61	Case II J. J. J. J. C. C. B. et al. Clinical findings in 111 across of influence A. (U7N0) wires infection. N
704	01.	Gao II-N, Ly II-2, Cao B et al. Chinical multips in 111 cases of influenza A (IT/N9) vitus infection. N
705	6	Lingi J Med. 2015,508.2277-2285. doi:10.1050/nejinoa1505564.
/06	62.	Jeyanathan T, Overgaard C, MGeer A. Cardiac complications of influenza infection in 3 adults. CMAJ.
/0/		2013;185(7):581-584. doi:10.1503/cmaj.110807.
708	63.	Wang J, Xu H, Yang X et al. Cardiac complications associated with the influenza viruses A subtype H7N9
709		or pandemic H1N1 in critically ill patients under intensive care. Braz J Infect Dis. 2017;21(1):12-18.
710		doi:10.1016/j.bjid.2016.10.005.
711	64.	Estabragh ZR, Mamas A. The cardiovascular manifestations of influenza: a systematic review. Int J
712		Cardiol. 2013;167(6):2397-2403. doi:10.1016/j.ijcard.2013.01.274.
713	65	Ito T Akamatsu K Likimura A et al. The prevalence and findings of subclinical influenza-associated
714	02.	cardiac abnormalities among Jananese natients Intern Med 2018:57(13):1819-1826
715		doi:10.2169/internalmedicine.0316-17
716	66	Charles D. Deter IV. Bishamutha V et al. Condisa manifestations in patients with pandamic (UINI) 2000
717	00.	Chacko B, Felel JV, Fichalhulta K et al. Calurac mannestations in patients with partennic (H1N1) 2009
/1/		virus infection needing intensive care. J Crit Care. 2012;27(1):e1-106. doi:10.1016/j.jcrc.2011.05.016.
/18	67.	Wells GA, Shea B, O'Connell D et al. 2019. The Newcastle-Ottawa Scale (NOS) for assessing the quality
/19		of nonrandomised studies in meta-analyses.
/20		http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 27 July 2020.
721	68.	Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic
722		reviews and meta-analysis: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
723		doi:10.1371/journal.pmed.1000097.
724	69.	Stroup AF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal
725		for reporting, JAMA, 2000;283(15);2008-2012, doi:10.1001/iama.283.15.2008.
726	70	Nehring SM, Goval A, Bansal P, Patel B C (2020), C Reactive Protein (CRP) [[Indated 2020] Jun 5]. In-
727	70.	Statbaarls Internati Trasura Island (EI): Statbaarls Dubliching Available from:
728		https://www.nchi.nlm.nih.gov/hooks/NBK441843/
729	71	Exelund S Manfred K Choosing cut-offs for NT-proRNP 2011 https://acutecaretesting.org/
730	, 1.	/media/acutecaretesting/files/ndf/choosing_cutoffs_for_ntprobum.pdf
731	72	Lindsey I.B. Kennedy K.F. Stolker I.M. Gilchrist I.C. Mukheriee D. Marso S.P. at al. (2011). Prognostic
732	12.	implications of Creatine Kinase-MB elevation after percutaneous coronary intervention. Circ Cardiovase
733		Interv A 474.480
, 33		<i>110011</i> , 1, 17 (100.

- 734 73. Madjid M, Vela D, Khalili-Tabrizi H, Casscells SW, Litovsky S. Systemic infections cause exaggerated
 local inflammation in atherosclerotic coronary arteries: clues to the triggering effect of acute infections on
 acute coronary syndromes. Tex Heart Inst J. 2007;34(1):11-18. PMID:17420787.
- 737
 74. Corrales-Medina VF, Musher DM, Shachkina S, Chirinos JA. Acute pneumonia and the cardiovascular system. Lancet. 2013;381(9865):496-505. doi:10.1016/S0140-6736(12)61266-5.
- 739 75. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43(5):970–976. doi:10.1161/01.HYP.0000124667.34652.1a.
- 742 76. Wang J, He W, Guo L et al. The ACE2-Ang (1-7)-Mas receptor axis attenuates cardiac remodeling and fibrosis in post-myocardial infarction. Molec Med Rep. 2017;16(2):1973-1981. doi:10.3892/mmr.2017.6848.
- 745 77. Ferrario CM, Jessup J, Chappell MC et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605–2610. doi:10.1161/circulationaha.104.510461.
- 748 78. Gheblawia M, Wang K, Viveirosa A et al. Angiotensin converting enzyme 2: SARSCoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ Res. 2020; doi:10.1161/CIRCRESAHA.120.317015.
- 751 79. Patel VB, Zhong JC, Grant MB, Oudit GY. Role of the ACE2/Angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ Res. 2016;118(8):1313 1326. doi:10.1161/CIRCRESAHA.116.307708.
- 80. Marchiano S, Hsiang T-Y, Higashi T, et al. SARS-CoV-2 infects human pluripotent stem cell-derived cardiomyocytes, impairing electrical and mechanical function. *bioRxiv*. 2020; doi: 10.1101/2020.08.30.274464.
- 81. Lindner D, Fitzek A, Brauninger H, et al. Association of cardiac infection with SARS-CoV-2 in confirmed
 COVID-19 autopsy cases. JAMA Cardiol. 2020; doi: 10.1001/jamacardio.2020.3551.
- Han MLK, McLaughlin VV, Criner GJ, Martinez FJ. Pulmonary diseases and the heart. Circulation.
 2007;116(25);2992-3005. doi:10.1161/CIRCULATIONAHA.106.685206.
- Forfia PR, Vaidya A, Wiegers SE. Pulmonary heart disease: the heart-lung interaction and its impact on patient phenotypes. Pulm Circ. 2013;3(1):5-19. doi:10.4103/2045-8932.109910.
- 84. Barnes M, Heywood AE, Mahimbo A, Rahman B, Newall AT, Macintyre CR. Acute myocardial infarction and influenza: a meta-analysis of case-control studies. Heart. 2015;101(21):1738-1747. doi:10.1136/heartjnl-2015-307691.
- 765 85. Carter P, Lagan J, Fortune C et al. Association of cardiovascular disease with respiratory disease. J Am Coll Cardiol. 2019;73(17):2166-2177. doi:10.1016/j.jacc.2018.11.063.
- 86. Ingebrigsten TS, Marott JL, Vestbo J, Nordestgaard BG, Lange P. Coronary heart disease and heart failure
 in asthma, COPD and asthma-COPD overlap. BMJ Open Resp Res. 2020;7:e000470. doi:10.1136/bmjresp-2019-000470.
- 87. Martinez-Mateo V, Fernandez-Anguita MJ, Paule A. Electrocardiographic signs of acute right ventricular
 hypertrophy in patients with COVID-19 pneumonia: A clinical case series. Electrocardiology.
 2020;62:100–102.
- 88. Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet. 2020; doi:10.1016/S2213-2600(20)30167-3.
- 89. Bermejo-Martin JF, Martin-Fernandez M, Lopez-Mestanza C, Duque P, Almansa R. Shared features of
 endothelial dysfunction between sepsis and its preceding risk factors (aging and chronic disease). J Clin
 Med. 2018;7(11):400. doi:10.3390/jcm7110400.
- 90. Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicated new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116(6):1097-1100. doi:10.1093/cvr/cvaa078.
- 91. Heather LC, Clarke K. Metabolism, hypoxia, and the diabetic heart. J Mol Cell Cardiol. 2011;50(4):598-605. doi:10.1016/j.yjmcc.2011.01.007.
- 92. Iqbal T, Welsby PJ, Howarth FC, Bidasee K, Adeghate E, Singh J. Effects of diabetes-induced hyperglycaemia in the heart: biochemical and structural alterations. In: Turan B, Dhalla N, editors. Diabetic Cardiomyopathy: Advances in Biochemistry in Health and Disease, vol 9. New York: Springer; 2014. ISBN:9781461493174.
- 787 93. Rask-Madsen C, King GL. Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab. 2013;17(1):20-33. doi:10.1016/j.cmet.2012.11.012.